Abstract The claudin18. 2 (CLDN18. 2) protein, an isoform of claudin18, a member of the
tight junction protein family, is a highly selective biomarker with limited expression in normal …

Immunotherapies boosting the immune system's ability to target cancer cells are promising
for the treatment of various tumor types, yet clinical responses differ among patients and …

Background Paediatric acute myeloid leukaemia (AML) is characterized by poor outcomes
in patients with relapsed/refractory disease, despite the improvements in intensive standard …

Adoptive transfer of genetically engineered chimeric antigen receptor (CAR) T cells is
becoming a promising treatment option for hematological malignancies. However, T cell …

Longitudinal studies have indicated the pivotal role of natural killer cells (NKs) in the
elimination of certain infections and malignancies. Currently, perinatal blood (PB) and cord …

Patients with Burkitt lymphoma who are refractory to initial therapy or who relapse after
undergoing intensive chemotherapy and autologous stem cell transplantation (ASCT) …

Advances in immuno‐oncology have provided a variety of novel therapeutics that harness
the innate immune system to identify and destroy neoplastic cells. It is noteworthy that …

The understanding of the relationship between immunological responses and cancers,
especially those related to HPV, has allowed for the study and development of therapeutic …

Leukemias are the most common type of pediatric cancer around the world. Prognosis has
improved during the last decades, and many patients are cured with conventional treatment …

Chimeric antigen receptors are synthetically produced receptors engineered to engage with
target cells with high specificity. These cells are created by inserting an artificial T-cell …